Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122539 | 0.90 | KDM4E (0.40) | LMNAALDH1A1TDP1TP53 | |
| SCHEMBL7114173 | 0.86 | THRB (0.43) | SMN1; SMN2ALDH1A1TP53MEN1KMT2A | |
| SCHEMBL7126531 | 0.84 | TRPA1 (0.53) | L3MBTL1SMN1; SMN2LMNAALDH1A1TP53 | |
| SCHEMBL7061008 | 0.82 | SMN1; SMN2 (0.45) | PKMSMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL7131191 | 0.81 | MMP1 (0.40) | L3MBTL1SMN1; SMN2LMNAALDH1A1NPSR1 | |
| SCHEMBL6679671 | 0.76 | MMP1 (0.40) | L3MBTL1SMN1; SMN2LMNAALDH1A1NPSR1 | |
| SCHEMBL6692406 | 0.75 | ALDH1A1 (0.36) | L3MBTL1ALDH1A1TSHR | |
| SCHEMBL7126749 | 0.74 | TRPA1 (0.42) | PKMLMNAALDH1A1TRPA1MEN1 | |
| SCHEMBL7115999 | 0.73 | TRPA1 (0.42) | PKMSMN1; SMN2LMNAALDH1A1NPSR1 | |
| SCHEMBL7120798 | 0.73 | MAPT (0.49) | SMN1; SMN2LMNAALDH1A1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | L3MBTL1 2277/4885PKM 2081/4885SMN1; SMN2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.